TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19843703

Group type: EXPERIMENTAL
Intervention: Culturally adapted diabetes lifestyle intervention
Number of subjects: 0
Study: 19843887

Group type: EXPERIMENTAL
Intervention: Lumiliximab (375 mg/m² or 500 mg/m²) combined with fludarabine, cyclophosphamide, and rituximab (FCR) for 6 cycles
Number of subjects: 31

Group type: COMPARATOR
Intervention: FCR alone (control group, not explicitly detailed in the abstract)
Number of subjects: 31
Study: 19843899

Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters (2 g/d, containing 930 mg EPA and 750 mg DHA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Corn oil placebo capsules
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Omega-3 acid ethyl esters
Number of subjects: 122
Study: 19843914

Group type: EXPERIMENTAL
Intervention: Low AT/AF burden (<5.5 hours)
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: High AT/AF burden (≥5.5 hours)
Number of subjects: 2486

Group type: COMPARATOR
Intervention: Zero AT/AF burden
Number of subjects: 2486

Group type: COMPARATOR
Intervention: Comparison of low vs zero burden
Number of subjects: 2486

Group type: COMPARATOR
Intervention: Comparison of high vs zero burden
Number of subjects: 2486
Study: 19845088

Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretations
Number of subjects: 1
Study: 19845588

Group type: EXPERIMENTAL
Intervention: PET/CT with [(18)F]FDG labeling of islets
Number of subjects: 5
Study: 19846059

Group type: EXPERIMENTAL
Intervention: Vitrectomy in pseudophakic eyes (group 1)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vitrectomy and cataract extraction as a combined procedure (group 2)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vitrectomy followed by cataract extraction (group 3)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vitrectomy on eyes that remained phakic (group 4)
Number of subjects: 130
Study: 19846066

Group type: EXPERIMENTAL
Intervention: TA-CD vaccine (82 microg, n = 4; 360 microg, n = 6) administered at weeks 1, 3, 5, and 9
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cocaine (0 mg, 25 mg, 50 mg)
Number of subjects: 10
Study: 19846634

Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 263

Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Multiplex PCR and Blood culture
Number of subjects: 263
Study: 19846730

Group type: EXPERIMENTAL
Intervention: Grade 2 diastolic dysfunction
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: LA volume index >32 mL/m(2)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Summed stress score on myocardial perfusion scintigraphy
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Valvulo-arterial impedance
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Summed stress score
Number of subjects: 305
Study: 19847907

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 19849892

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 30
Study: 19850249

Group type: EXPERIMENTAL
Intervention: Combination-facilitated PCI (abciximab plus half-dose reteplase)
Number of subjects: 2452

Group type: COMPARATOR
Intervention: Abciximab alone
Number of subjects: 2452

Group type: COMPARATOR
Intervention: Spoke site alone (no facilitated PCI)
Number of subjects: 2452
Study: 19850258

Group type: EXPERIMENTAL
Intervention: Resolute stent
Number of subjects: 139
Study: 19850694

Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (rhTSH)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Thyroid hormone withdrawal (L-T4)
Number of subjects: 51
Study: 19850844

Group type: EXPERIMENTAL
Intervention: Patients with dry eye syndrome (including Sjögren's syndrome)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patients with Sjögren's syndrome
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patients with dry eye syndrome
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CXCL10 levels
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CXCL11 levels
Number of subjects: 33
Study: 19851652

Group type: EXPERIMENTAL
Intervention: Positive AKI (+) group
Number of subjects: 817

Group type: COMPARATOR
Intervention: Negative AKI (-) group
Number of subjects: 817
Study: 19852906

Group type: EXPERIMENTAL
Intervention: Predrafting personal factors (behavioral assessment, cognitive assessment, linguistic ability, and education)
Number of subjects: 2362

Group type: EXPERIMENTAL
Intervention: Cognitive functioning, education, rank, and position during the trauma
Number of subjects: 2362

Group type: EXPERIMENTAL
Intervention: Predrafting psychological assessment of social and individual qualifications
Number of subjects: 2362

Group type: COMPARATOR
Intervention: Behavioral assessment
Number of subjects: 2362

Group type: COMPARATOR
Intervention: Training
Number of subjects: 2362
Study: 19852963

Group type: EXPERIMENTAL
Intervention: Des-gamma-carboxy prothrombin (DCP) at month 0 with cutoff of 40 mAU/mL
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Des-gamma-carboxy prothrombin (DCP) at month 0 with cutoff of 150 mAU/mL
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alpha-fetoprotein (AFP) at month 0 with cutoff of 20 ng/mL
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alpha-fetoprotein (AFP) at month 0 with cutoff of 200 ng/mL
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Des-gamma-carboxy prothrombin (DCP) at month -12 with low cutoff
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alpha-fetoprotein (AFP) at month -12 with low cutoff
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of DCP and AFP
Number of subjects: 39

Group type: COMPARATOR
Intervention: Surveillance ultrasound
Number of subjects: 39

Group type: COMPARATOR
Intervention: Doubling of AFP
Number of subjects: 39

Group type: COMPARATOR
Intervention: Combination of tests
Number of subjects: 39
Study: 19853693

Group type: COMPARATOR
Intervention: TIMI flow 3 post-PCI
Number of subjects: 1018

Group type: COMPARATOR
Intervention: TMPG 2/3 post-PCI
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Residual ST elevation <2 mm
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Post-PCI TMPG 2/3
Number of subjects: 1018
Study: 19853837

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention at workstation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 19854499

Group type: EXPERIMENTAL
Intervention: AAV2-hRPE65v2 gene therapy (1.5 x 10(10) vector genomes, 4.8 x 10(10) vector genomes, 1.5 x 10(11) vector genomes)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AAV2-hRPE65v2 gene therapy
Number of subjects: 12
Study: 19854509

Group type: EXPERIMENTAL
Intervention: Heavy water ((2)H(2)O) labelling for 6 weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: RosetteSep-based method for CLL cell isolation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Heavy water ((2)H(2)O) labelling
Number of subjects: 29
Study: 19855289

Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bimatoprost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 0
Study: 19856395

Group type: EXPERIMENTAL
Intervention: Study medication adherence (MedAd)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Study visit adherence (VAd)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Medication adherence during dose titration
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (SES) influence on adherence
Number of subjects: 191
Study: 19857703

Group type: EXPERIMENTAL
Intervention: Heart transplantation for light patients (below 80 kg)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Heart transplantation for heavy patients (80 kg or above)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Waiting time for light patients (below 80 kg)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Waiting time for heavy patients (80 kg or above)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Deaths before transplantation for light patients (below 80 kg)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Deaths before transplantation for heavy patients (80 kg or above)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Factors related to not receiving a heart transplant
Number of subjects: 658
Study: 19857702

Group type: EXPERIMENTAL
Intervention: NTproBNP
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: HFSS
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Combined model of NTproBNP, hsCRP, and HFSS
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Composite endpoint (death or urgent transplantation)
Number of subjects: 658
Study: 19858149

Group type: EXPERIMENTAL
Intervention: G6PD gene variant
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: UGT1A1 gene variant
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: SLCO1B1 gene variant
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Coexpression of G6PD African A- mutation with UGT1A1 and/or SLCO1B1 variants
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Factors contributing to hyperbilirubinemia
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: ABO blood group heterospecificity (mother had blood group O)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Positive direct Coombs test results
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Sibling treated with phototherapy
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Maternal circulating blood group antibodies
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Maternal diabetes mellitus
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Maternal East Asian ethnicity
Number of subjects: 452
Study: 19858174

Group type: EXPERIMENTAL
Intervention: Nutritious, culturally appropriate daily meal (weeks 1-8) and food package (weeks 9-32) (n=137)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Nutritional advice (n=133)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Patients with positive results on sputum smears receiving nutritious meal
Number of subjects: 270

Group type: COMPARATOR
Intervention: Patients with positive results on sputum smears receiving nutritional advice
Number of subjects: 270
Study: 19858707

Group type: EXPERIMENTAL
Intervention: Ultrasound guided conservative procedure (mini-mesohepatectomy)
Number of subjects: 17
Study: 19858725

Group type: EXPERIMENTAL
Intervention: Framingham risk model
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: SCORE risk model
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Chest pain
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Prior cardiovascular disease (CVD)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: hs-CRP >or=2 mg/l in patients without prior CVD and LDL <3.4 mmol/l
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 539
Study: 19858759

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study: 19863224

Group type: EXPERIMENTAL
Intervention: Dendritic cell-based vaccination with allogeneic melanoma cell lysate
Number of subjects: 0
Study: 19864401

Group type: EXPERIMENTAL
Intervention: Dietary intake of fish (1-2 servings, 25-50 g/week)
Number of subjects: 204

Group type: COMPARATOR
Intervention: <101 g fish/week
Number of subjects: 204

Group type: COMPARATOR
Intervention: >=101 g fish/week
Number of subjects: 204
Study: 19875605

Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood infusion
Number of subjects: 15
Study: 19875989

Group type: EXPERIMENTAL
Intervention: Self-reported TV-viewing time
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Objective TV-viewing time measured by electronic monitors
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-reported TV-viewing time vs. objective measure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-reported viewing time accuracy
Number of subjects: 40
Study: 19877976

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and Cognitive-Behavioral Therapy (COMB)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Pill Placebo (PBO)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX) or Cognitive-Behavioral Therapy (CBT)
Number of subjects: 439
Study: 19879222

Group type: EXPERIMENTAL
Intervention: Recombinant hemagglutinin (rHA)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Trivalent inactivated vaccine (TIV)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Both rHA and TIV
Number of subjects: 869
Study: 19879566

Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum-assisted closure (E-VAC)
Number of subjects: 8
Study: 19880144

Group type: EXPERIMENTAL
Intervention: Epicardial left atrial appendage clip placement
Number of subjects: 34
Study: 19880498

Group type: EXPERIMENTAL
Intervention: Gene expression classifier predictive of relapse-free survival (RFS)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Gene expression classifier
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Flow cytometric measures of minimal residual disease (MRD)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Combined gene expression classifier
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 21-gene expression classifier predictive of end-induction MRD
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Gene expression classifiers
Number of subjects: 207
Study: 19880781

Group type: EXPERIMENTAL
Intervention: Multiparameter flow cytometry
Number of subjects: 765

Group type: COMPARATOR
Intervention: Conventional morphology
Number of subjects: 765
Study: 19880906

Group type: EXPERIMENTAL
Intervention: High-resolution CT (HRCT) scanning
Number of subjects: 92

Group type: COMPARATOR
Intervention: Tuberculin skin test (TST) and QuantiFERON TB Gold In-Tube (QFT) test
Number of subjects: 92

Group type: COMPARATOR
Intervention: CXR
Number of subjects: 92
Study: 19880908

Group type: EXPERIMENTAL
Intervention: Trained patients (n = 10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Untrained patients (n = 7)
Number of subjects: 17
Study: 19882494

Group type: EXPERIMENTAL
Intervention: Directional hearing aids for 1 month
Number of subjects: 94

Group type: COMPARATOR
Intervention: Omnidirectional hearing aids for 1 month
Number of subjects: 94
Study: 19882497

Group type: EXPERIMENTAL
Intervention: Prior participation in pulmonary rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater exercise capacity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-perception of being disabled
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral corticosteroid use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise capacity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-breath diffusing capacity of the lung for carbon monoxide percent predicted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-minute walk test distance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FEV(1)
Number of subjects: 0
Study: 19886987

Group type: EXPERIMENTAL
Intervention: Protracted 5FU intravenous infusion (200 mg/m2 daily) plus LAR octreotide (20 mg monthly)
Number of subjects: 29
Study: 19887595

Group type: EXPERIMENTAL
Intervention: Exercise training for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forskolin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AICAR treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Ionomycin treatment)
Number of subjects: 0
Study: 19888782

Group type: EXPERIMENTAL
Intervention: Triptorelin embonate (pamoate) 22.5 mg, two consecutive intramuscular injections at an interval of 24 weeks
Number of subjects: 120
Study: 19889129

Group type: EXPERIMENTAL
Intervention: Galantamine-ER 8-24 mg/day for 4 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Baseline (healthy volunteers)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Galantamine-ER treatment
Number of subjects: 19
Study: 19889232

Group type: EXPERIMENTAL
Intervention: Recombinant human methionyl leptin (r-metHuLeptin)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Withdrawal of leptin during six weeks
Number of subjects: 4
Study: 19889819

Group type: EXPERIMENTAL
Intervention: 400 mg phytosterols/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2000 mg phytosterols/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: 59 mg phytosterols/d (control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 459 mg phytosterols/d
Number of subjects: 18
Study: 19890127

Group type: EXPERIMENTAL
Intervention: Synthetic peptide-based erythropoietin-receptor agonist (Hematide); administered subcutaneously at an initial dose of 0.05 mg/kg every 4 weeks
Number of subjects: 14
Study: 19890203

Group type: EXPERIMENTAL
Intervention: Lopinavir 400 mg and Ritonavir 100 mg, given twice daily for 4 weeks
Number of subjects: 8
Study: 19891771

Group type: EXPERIMENTAL
Intervention: Bispectral Index monitor (BIS) with electronic alerts if BIS value is >60
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Minimum alveolar concentration (MAC) with electronic alerts if age-adjusted MAC is <0.5
Number of subjects: 30000
Study: 19892043

Group type: EXPERIMENTAL
Intervention: Booster vaccination at Year 5
Number of subjects: 0

Group type: COMPARATOR
Intervention: No booster vaccination at Year 5 (unboosted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose at Year 20 for both groups
Number of subjects: 0
Study: 19892587

Group type: EXPERIMENTAL
Intervention: Gene transfer using aquaporin-1 cDNA via a recombinant adenoviral vector
Number of subjects: 0
Study: 19897179

Group type: EXPERIMENTAL
Intervention: Repeated-dose intravenous ketamine (six infusions over 12 days)
Number of subjects: 10
Study: 19897553

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Flexible bronchoscopy
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound following negative flexible bronchoscopy
Number of subjects: 137
Study: 19898830

Group type: EXPERIMENTAL
Intervention: Physical activity (commuting and leisure-time)
Number of subjects: 4031

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 4031
Study: 19898832

Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp test
Number of subjects: 38

Group type: COMPARATOR
Intervention: OGTT
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Clamp-derived functional variables
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low first-phase C-peptide response
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low second-phase C-peptide response
Number of subjects: 38
Study: 19901114

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg on days 1-21 of a 28-day cycle) plus high-dose dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for the first four cycles, then 40 mg on days 1-4 only thereafter)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulation
Number of subjects: 353

Group type: COMPARATOR
Intervention: Control group (dexamethasone plus placebo)
Number of subjects: 353
Study: 19901191

Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein (rHDL) infusion (CSL-111; 20 mg . kg(-1) . h(-1)) for 4 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study: 19902266

Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment for patent ductus arteriosus (PDA)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No ibuprofen treatment
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment for PDA
Number of subjects: 148
Study: 19906082

Group type: EXPERIMENTAL
Intervention: Single intravitreal injection of triamcinolone combined with bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19906624

Group type: EXPERIMENTAL
Intervention: Tenofovir and emtricitabine once daily plus nevirapine twice daily
Number of subjects: 10
Study: 19906626

Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) and Lopinavir/Ritonavir (LPV/r)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 10
Study: 19907027

Group type: EXPERIMENTAL
Intervention: Transient elevation of IOP to an average of 64 mm Hg for less than 30 seconds in one eye of all subjects.
Number of subjects: 100
Study: 19909496

Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (high intensity levels > 3.9 g)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (first three months of exercise exceeding 1.1 g)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (first three months of activity)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (0-6 months' impacts)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (6 months of training)
Number of subjects: 35
Study: 19909747

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Virtual chromoendoscopy
Number of subjects: 75
Study: 19910250

Group type: EXPERIMENTAL
Intervention: Optical diagnosis using high-definition white light, narrow-band imaging without magnification, and chromoendoscopy as required.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Optical diagnosis alone for determining surveillance intervals.
Number of subjects: 130
Study: 19912627

Group type: EXPERIMENTAL
Intervention: TABADO program (smoking cessation program combining pharmacologic and cognitive-behavioral strategies)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: No specific intervention (control group)
Number of subjects: 2000